Menu
← Oncology Approval Tracker
FDA DECISION ·
Brukinsa tablets
zanubrutinib · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A 160 mg scored tablet presentation for adults with Waldenström macroglobulinemia or chronic lymphocytic leukemia/small lymphocytic lymphoma.
LAMPGEN ANALYSIS
Why it matters
The tablet gives patients an alternate presentation for these established BTK inhibitor indications.
What research teams should watch
Confirm the prescribed strength and total daily dose when transitioning from capsules, and track the relevant use’s regulatory pathway separately.
PRIMARY RECORDS